ESR1 and breast carcinoma: Further, until there are data to establish that PR is a predictive (and not merely prognostic) marker in ER+ breast cancer (and outperforms competing predictive biomarkers in ER+ breast cancer), the clinical rationale for routine PR testing in ER+ breast cancer will remain uncertain.